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Abstract The 2008 WHO Classification of Tumors of
Haematopoietic and Lymphoid Tissues has introduced two
new categories of high-grade B-cell lymphomas: entities in
which features of diffuse large B-cell lymphoma (DLBCL)
overlap with Burkitt lymphoma (DLBCL/BL) or classical
Hodgkin lymphoma (DLBCL/HL). The DLBCL/BL cate-
gory encompasses cases that resemble Burkitt lymphoma
morphologically, but have one or more immunophenotypic
or molecular genetic deviations that would exclude it from
the BL category; conversely, some cases have immunophe-
notypic and/or genetic features of BL, but display cytologic
variability unacceptable for BL. Many of the cases in the
DLBCL/BL category contain a translocation of MYC as
well as either BCL2 or BCL6 (so-called double-hit
lymphomas) and have a very aggressive clinical behavior.
The DLBCL/HL category encompasses lymphomas that
exhibit the morphology of classical Hodgkin lymphoma but
the immunophenotype of DLBCL, or vice versa. Most
DLBCL/HL cases described present as mediastinal masses,
but this category is not limited to mediastinal lymphomas.
These new categories acknowledge the increasing recogni-
tion of cases that display mixed features of two well-
established diseases. Whether the existence of such cases
reflects shortcomings of our current diagnostic armamen-
tarium or a true disease continuum in which such hybrid or
intermediate neoplasms actually exist remains to be
determined.
Keywords Burkitt.DiffuselargeB-celllymphoma.
Hodgkinlymphoma.Grayzonelymphoma
Introduction
Classification systems represent the language of both
pathology and clinical medicine and provide a critical
communication medium in establishing, applying, and
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e-mail: L.deLeval@ulg.ac.bevalidating therapeutic protocols. The 2008 WHO Classifi-
cation of Tumors of Haematopoietic and Lymphoid Tissues
has refined the 2001 Classification based on new and
accumulated experimental evidence. Increasingly, diagnos-
tic criteria are based on more diverse types of information
than mere morphology, such as clinical information,
immunophenotype, and (particularly in the 2008 Classifi-
cation), molecular genetic studies [1]. However, this ever
diversifying armamentarium of tools to interrogate neo-
plasms has an “Achilles Heel”: tumors are inherently
complex and do not necessarily provide predictable
answers to our broad range of studies. These complexities
can stymie our attempts to force individual cases into a
particular category by several ways: the tumor may lie on a
true biologic continuum between two entity definitions; it
may exhibit an exceptional clinical behavior, morphology,
immunophenotype, or genetic finding that mimics another
tumor type; it may appear to change from one tumor type to
another; or it may contain subclones that appear as two
discrete tumors. In recognition of the inherent complexity
of aggressive B-cell lymphomas, the WHO 2008 Classifi-
cation has created two new categories for tumors that
appear to lie on the continuum between diffuse large B-cell
lymphoma (DLBCL) and Burkitt lymphoma (BL), and
between DLBCL and classical Hodgkin lymphomas (CHL).
While these new categories may prove to be frustrating to
clinicians who wish to treat their patients for a familiar
disease with a tested therapy, they acknowledge the
current reality that optimal therapy for these overlapping
entities is unclear. Moreover, the creation of these
diagnostic categories maintains the “purity” of existing
entities (DLBCL, BL, CHL), as the inclusion of borderline
cases may compromise (and has most likely already
compromised) the validity of studies that use looser
inclusion criteria.
Current “state of the art” of Burkitt lymphoma
The 2008 WHO Classification continues to recognize
three epidemiologic variants of BL (endemic BL, sporadic
BL, and immunodeficiency-associated BL), but the previ-
ous atypical/Burkitt-like and plasmacytoid morphologic
variants are no longer formally designated. Cases of BL
that have features slightly deviating from the typical
medium-sized monomorphous cytomorphology, such as
increased nuclear irregularity, slight nuclear pleomorphism,
and/or more prominent, single nucleoli (including most
cases arising in adults) are classified simply as BL if they
otherwise fit immunophenotypically and genetically. This
change is supported by recent data showing that these
morphologically “atypical” BL cases have a molecular
signature similar to classic BL [2]. BL cases presenting as a
leukemia without significant lymphadenopathy (previously
known as ‘L3’ ALL) are retained within the BL category
and represent the only recognized BL variant in the 2008
WHO Classification.
The characteristic immunophenotype of BL is that of
strong CD10 expression, expression of BCL6, negativity
for BCL2, and a Ki67 proliferation index (PI) of near 100%
(at least 90% of tumor cells) [3]. Immunohistochemistry for
MYC protein is non-specific and is not useful for
diagnostic purposes. The MYC rearrangement in BL usually
occurs in a background of a relatively simple karyotype and
should lack concomitant rearrangements of BCL2 or BCL6
[2, 4]. Two major recent gene expression profiling studies
have shown that typical BL cases have a characteristic
molecular signature [2, 5]. Rare cases that are otherwise
characteristic for BL lack a MYC translocation; the
proportion of BL cases that are MYC negative is variable
in published studies, likely reflecting differing pathologic
inclusion criteria. These cases bear a molecular signature
similar to BL cases that have rearranged MYC, validating
their classification as BL [2, 5]. Recent data suggest that
BL cases lacking a MYC rearrangement may upregulate
MYC expression by alternative mechanisms, possibly
involving the modulation of microRNAs [6].
B-cell lymphoma unclassifiable, with features
intermediate between diffuse large B-cell lymphoma
and Burkitt lymphoma
With the increasing use of detailed immunophenotyping
panels and genetic studies, there has been increased
recognition of cases that share many features with BL, but
differ with respect to one or more findings. There has been
poor reproducibility when pathologists attempt to assign
such cases to BL or DBLCL categories, even when
integrating ancillary laboratory results such as cytogenetics
and immunophenotype [7]. The molecular profiling study
of Hummel et al. also identified a group of cases displaying
a molecular signature intermediate between BL and
DLBCL. Moreover, some cases classified by pathologists
as DLBCL bore a molecular signature of BL. These
findings suggest that a true continuum between these
entities may exist [2, 5]. Nevertheless, given the different
therapies that are indicated, pathologists’ hedging between
BL and DLBCL is frustrating for clinicians and also affects
the validity of clinical trials that aim to evaluate the
effectiveness of therapies on discrete diagnostic entities.
For these reasons, the WHO 2008 Classification established
a new diagnostic category of B-cell lymphoma, unclassifi-
able, with features intermediate between DLBCL and BL
(DLBCL/BL). These cases have morphologic, immunophe-
notypic, and genetic features that include aspects of both
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classified into either category.
DLBCL/BL cases consist largely of cases in which the
pathologist considers a diagnosis of BL, but which are
excluded from the category. Cases with an immunopheno-
type of BL (including a PI >90%) and with “starry-sky”
appearance, but with marked variation in cytomorphology
that is not acceptable for BL, are classified as DLBCL/BL.
Conversely, cases that have morphology that is acceptable
for BL (uniform or mildly pleomorphic medium-sized cells)
may be placed into the DLBCL/BL category if they do not
have the typical immunophenotype of BL; while occasional
BL cases may have minor immunophenotypic deviations,
such as weak positivity for BCL2, strong BCL2 staining,
and/or a Ki67 proliferation index of <90% are strong
contraindications for a diagnosis of BL. Similarly, cases
resembling BL with MYC rearrangements that are trans-
formations of a documented prior low-grade B-cell lym-
phoma are classified as DLBCL/BL [8]. Rare cases
resembling B-lymphoblastic leukemia/lymphoma (B-LBL)
by morphology, TdT positivity, and negativity for surface
immunoglobulin may bear a MYC rearrangement with or
without a BCL2 rearrangement [9, 10]. It is controversial
whether to diagnose these cases as B-LBL or as DLBCL/
BL. However, both of these entities are treated similarly
with intensive chemotherapy regimens. Importantly, B-cell
lymphomas composed of large cells or those with marked
cellular pleomorphism should be classified as DLBCL
irrespective of their MYC status, proliferation index, or
immunophenotype: indeed, up to 15% of DLBCL cases
bear a MYC translocation [11, 12] and some DLBCL cases
may have proliferation indices approaching 100% [13].
Although some of these cases have been shown to bear the
molecular signature of BL, using current diagnostic
methods they must be classified as DLBCL.
When a MYC rearrangement is present in DLBCL/BL
cases, it often has atypical features, including one or more
of the following: (1) rearrangement with a non-IG partner;
(2) as part of a complex karyotype; (3) concurrent
rearrangements of BCL2 and/or BCL6 genes (so-called
double-hit or triple-hit lymphoma lymphomas). “Double-
hit” lymphomas with both MYC and BCL2 rearrangements
comprise a large and relatively well-characterized subset of
DLBCL/BL. These cases exhibit a spectrum of morphology
and a wide range of Ki67 proliferation index, but all
strongly express BCL2 [14]. Rare cases of histologically
low-grade follicular lymphoma that bear both MYC and
BCL2 rearrangements should not be placed into this
category, as these are histologically distinct [14, 15]. Rare
cases of plasma cell myeloma may also bear a MYC or
concurrent MYC and BCL2 rearrangements and should not
be included in the DLBCL/BL category [14, 16]. Although
gene expression profiling data is not available on DLBCL/
BL as a group, some “double-hit” cases with both MYC and
BCL2 rearrangement have been shown to have a molecular
signature similar to classic BL; other cases have a signature
intermediate between BL and DLBCL [5]. Importantly,
most cases of DLBCL with MYC translocation share the
molecular signature of DLBCL, not BL [5].
The “double-hit” DLBCL/BL lymphomas are highly
aggressive tumors that usually present with high stage of
disease and appear to do poorly whether treated with
intensive regimens used to treat BL or CHOP-like regimens
[13, 17–19]. The aggressive nature of these tumors likely
reflects their simultaneous expression of both pro-
proliferative (MYC) and anti-apoptotic (BCL2) oncopro-
teins. The clinical behavior of other cases fulfilling criteria
for DLBCL/BL (such as cases with overlapping features of
BL and DBLCL but lacking a “double-hit” or even a MYC
rearrangement) is unknown. It is anticipated that DLBCL/
BL represents a biologically heterogeneous group that
requires further genetic and clinical characterization.
Questions and controversies
What is the “gold standard” for a diagnosis of BL? The
two recent gene expression profiling studies validated the
genetic homogeneity of typical BL cases [2, 5]. However, a
substantial number of cases that would not be classified as
BL (17–34%, most likely including both DLBCL/BL and
DLBCL cases according to 2008 WHO Classification
criteria) had a molecular signature of BL. Cases with BL
molecular signature did poorly as a group when treated
with CHOP-like regimens. Conversely, BL and high-
proliferation DLBCL cases diagnosed by conventional
criteria and treated with intensive regimens had similar
outcome in one recent study [13]. Ultimately, the biologic
“gold standard” of BL is that of an aggressive, but (with
appropriately intensive chemotherapy) highly curable lym-
phoma. A prospective study is required to determine
whether molecular signature, WHO classification, or a
specific biologic marker (such as MYC translocation status
or Ki67 proliferation index) most optimally identifies cases
with this particular disease biology.
Should a MYC rearrangement be sought on all highly
proliferative B-cell neoplasms? According to the 2008
WHO Classification, a diagnosis of BL can be made if
the morphology and immunophenotype are perfect. In
children, in whom classic morphology predominates, a
MYC rearrangement is probably not necessary to confirm
the diagnosis. Similarly, a case with overt DLBCL
morphology does not require MYC investigation for
classification, since DLBCL/BL would not be a diagnostic
consideration (although it should be noted that MYC
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high proliferation index, and may provide helpful prognos-
tic information in certain clinical contexts) [13]. Accord-
ingly, it is probably prudent to assess for a MYC
rearrangement in all adult patients in which BL or BL/
DLBCL is a diagnostic consideration based on the
morphology and immunophenotype.
When should BCL2 and BCL6 rearrangements be
sought? Because the relative incidence of DLBCL/BL
appears to increase with age, while that of BL decreases,
it is probably prudent to examine any adult case of putative
BL for concomitant BCL2 and BCL6 rearrangements that
would argue against a diagnosis of BL. MYC rearranged
cases with concomitant BCL2 or BCL6 rearrangements
would be classified as DLBCL/BL, irrespective of the other
features. These “double-hit” lymphomas have a much
poorer prognosis than BL, even when treated with intensive
chemotherapy regimens.
What about looking for complex karyotype and MYC
rearrangement with non-IG partners? Different centers
vary in the practice of obtaining cytogenetics on lymph
node samples. Comparative genomic hybridization (CGH),
that shows markedly different complexity patterns in BL
and DLBCL, is not routinely available. Thus, while the
presence of a known complex karyotype would tend to
favor a diagnosis of DLBCL/BL over BL, practical
limitations such as lack of suitable material for classical
cytogenetics or non-availability of CGH (especially if only
paraffin material is available) impede routine performance
in many laboratories. Similarly, probes to assess the
rearrangement of MYC with non-IG gene loci are not
widely available. Nevertheless, if performed, the knowl-
edge that MYC is rearranged with a non-IG locus may be
helpful in assigning borderline cases (such as those with
minor immunophenotypic or morphologic deviations from
BL) to the DLBCL/BL category.
Primary mediastinal (thymic) large B-cell lymphoma
and its borderlands with classical Hodgkin lymphoma
Primary mediastinal large B-cell lymphoma (PMBL) was
the first large B-cell lymphoma entity to be delineated, by
virtue of its distinctive clinical and morphological features
[20, 21]. In contrast to other DLBCLs, PMBL tends to
occur in younger patients, with a predilection for women,
and usually presents as a localized, but often bulky anterior
mediastinal mass with or without involvement of supra-
clavicular lymph nodes [20, 22]. Distinctive morphological
features of PMBL include fine compartmentalizing sclerosis,
the presence of cells with abundant clear cytoplasm and/or
multilobated nuclei, and the presence of large Reed–
Sternberg-like cells [23].
In the 20 years that have elapsed since the original
descriptions of PMBL, further evidence has accumulated
that supports the concept of a disease distinct from non-
mediastinal DLBCL. The neoplastic B-cells express B-cell
antigens, but often lack surface immunoglobulin (Ig),
despite expression of the Ig-associated transcription factors
BOB1, OCT2, and PU1 [24]. Expression of antigens related
to the germinal center and post-germinal center stages of B-
cell differentiation is variable, but most cases co-express
BCL6 and MUM1/IRF4, often in the absence of CD10,
suggesting an activated or post-geminal center phenotype
[24, 25]. The majority of tumors express CD30, usually
heterogeneously and with weak to moderate intensity. The
frequent expression of CD23 and MAL in PMBL has been
taken as evidence to suggest its cellular derivation from an
immunophenotypically similar peculiar population of “as-
teroid” B cells normally present in the thymic medulla [26–
28]. In distinction from other DLBCLs, expression of FIG1
(the product of the interleukin-4-induced gene 1) and TNF-
receptor-associated factor 1 are characteristic of PMBL,
especially when combined with nuclear c-REL localization
[27, 29, 30]. Finally, the PMBL molecular signature differs
from that of other DLBCLs [29, 31].
In practice, the diagnosis of PMBL requires the
integration of the pathological and clinical presenting
features. It must be stressed that the particular features
listed above, albeit characteristic of PMBL, are not present
in every case, and none is entirely specific. Moreover,
among the different immunophenotypic markers that are
differentially expressed in PMBL and other DLBCL, only
CD23 and CD30 are available routinely in most diagnostic
laboratories. In young patients with disease localized to the
mediastinum (sometimes also involving supraclavicular
nodes), histopathologic documentation of DLBCL is nearly
always considered diagnostic of PMBL. In older patients,
secondary mediastinal involvement by DLBCL is more
common: in that setting, the characteristic features of
PMBL should be demonstrated and it is preferable to restrict
a PMBL diagnosis to cases that show the typical clinical and
pathological features. Both entities are currently treated with
anthracycline-based chemotherapy plus rituximab, and when
adjusted for stage, have similar outcomes.
PMBL and nodular sclerosis CHL (NSHL) exhibit
strikingly similar clinical presentations, as both diseases
tend to occur as a localized mediastinal mass in young
women. Moreover, in addition to some morphologic
overlap (Reed–Sternberg-like cells and sclerosis), recent
studies have documented many genetic and molecular
similarities [29, 31]. However, importantly for diagnostic
purposes, usual cases of PMBL and CHL also have several
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similarities and contrasting features of PMBL and CHL
are summarized in Table 1. The diagnosis of NSHL requires
a nodular growth pattern, broad bands of fibrosis, and lacunar
variants of Reed–Sternberg cells that have a characteristic
immunophenotype (CD45−, CD30+, CD15+/−). Unlike
CHL, the neoplastic cells of PMBL express CD45 and are
characteristically CD15−. CD30 expression, when present, is
typically weaker compared to the uniformly strong CD30
expression in CHL. Conversely, expression of B-cell
associated antigens is strong and uniform in PMBL, and is
usually weaker and more heterogeneous in the neoplastic
cells of CHL. While Ig is not typically expressed in the
neoplastic cells of either entity, Ig transcription factors such
as OCT2 and BOB1 are maintained in PMBL, and may be
absent in CHL. EBV may be present in CHL, but is absent
in PMBL.
B-cell lymphoma, unclassifiable, with features
intermediate between diffuse large B-cell lymphoma
and classical Hodgkin lymphoma
Even after using differential diagnostic criteria, a small
proportion of mediastinal large cell lymphomas cannot be
classified. These cases, previously termed “gray zone
lymphomas” or “large B-cell lymphomas with Hodgkin
features” in the literature, represent a spectrum of tumors
having characteristics of both PMBL and CHL [32–35]. In
the 2008 WHO Classification, a novel category designated
B-cell lymphoma, unclassifiable, with features intermediate
between diffuse large B-cell lymphoma and Hodgkin
lymphoma (DLBCL/HL) has been created to include these
neoplasms [1]. DLBCL/HL mostly encompasses lympho-
mas with mediastinal presentation, but also includes
occasional cases with features intermediate between
Table 1 Overlapping and contrasting features between primary mediastinal large B-cell lymphoma (PMBL) and mediastinal classical Hodgkin
lymphoma, nodular sclerosis type (NSHL)
PMBL NSHL
Clinical
presentation
Common to both
•Young adults, female predominance
•Mediastinal mass involving thymus and supraclavicular nodes
•Often localized disease (stages I–II)
Involvement of other distant extranodal sites at presentation or upon
recurrence
Usually no involvement of other extranodal sites
Morphology Fine compartimentalizing sclerosis, diffuse pattern Broad bands of collagen fibrosis, nodular pattern
Medium to large clear cells, Reed–Sternberg-like cells can be present Reed–Sternberg cells, lacunar cells
Sheets of tumor cells, little or no inflammatory background Scattered neoplastic cells in an inflammatory
background
Immunophenotype Common to both
•Absent or decreased expression of Ig and HLA
•Expression of MUM1/IRF4
CD45 Positive Negative
CD30 Often positive, usually weak Positive, strong
CD15 Negative Positive (85% of cases)
CD20 Positive Negative or weak
CD79a Positive Negative
Pax5 Strong Weak
BOB1 and OCT2 Positive Usually negative (one or both)
MAL Usually positive May be positive
EBV Absent May be present
Genetic features Common to both [36–38]
•Gain at 2p15: REL locus
•Gain at 9p24: JAK2 locus
Molecular features Common to both
•Decreased of BCR pathway signaling and constitutive NF-kappaB activation, [29, 38, 39]
•Activation of the cytokine-JAK-STAT pathway, [40–42]
•High expression of extracellular matrix elements, overexpression of the TNF family members
•Aberrant activation of the PI3K/AKT pathway [43]
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ed all other possible diagnoses (in particular EBV-positive
DLBCL of the elderly) have been excluded. For mediasti-
nal tumors, such a diagnosis should be restricted to cases
showing significant overlapping features, in particular
marked diagnostic discordance between the morphology
and immunophenotype. Features that would qualify a case
as DLBCL/HL include: (1) strong expression of CD15 in a
case otherwise resembling large B-cell lymphoma; (2)
strong and diffuse expression of CD20 and/or other B-cell
markers such as CD79a in a case morphologically
suggestive of CHL but very rich in large neoplastic cells.
Such cases support the existence of a spectrum of lympho-
mas that lie along a continuum between PMBL and CHL
[35] and further validate the demonstrated molecular link
between these entities. PMBL and CHL may also coexist in
some patients as simultaneous composite lesions or as
sequential tumors, the typical scenario being CHL occurring
first, followed by PMBL within the first few years [32, 35].
A clonal relationship has been demonstrated in some of such
sequential cases. The clinical relevance of this “unclassifi-
able” category is uncertain, but it has been suggested that the
clinical outcome of DLBCL/HL cases may be less favorable
than that of either PMBL or CHL. There is currently no
consensus on treatment for this entity, although some groups
have recommended treating these cases as aggressive B-cell
lymphomas [35].
These “borderline cases” are always diagnostically
difficult; workup of such cases should include most of
the markers suggested in Table 1 (including the B-cell
transcription factors OCT2 and BOB.1). While there is no
current precise recommendation regarding the weight to
put on each specific immunostain, there is general
agreement that DLBCL/HL includes cases in which the
immunoprofile is markedly different from that expected
from the morphology.
Conclusion
The designation of these two new “gray zone” case groups
as formal diagnostic entities has taken some pressure off
pathologists who previously felt compelled to classify the
unclassifiable. However, one potential concern is that these
new diagnoses may attract cases that display only minor
diversity within the established entities of BL, DLBCL, and
CHL. To avoid this, it is important that the diagnostic
spectra of BL, DLBCL, and CHL be clearly defined so that
only the truly intermediate or hybrid cases are included
within the new entities. Also, we must acknowledge and
accept that these intermediate categories do not represent
single diseases: they likely encompass multiple biologic
entities or, alternatively, may represent a mixture of cases of
each “parent” entity that we do not yet know how to
properly assign. The true “gold standard” that defines even
well-known neoplasms such as BL or MLBL is as yet
unknown. Perhaps with further study, particular markers
may be discovered that will allow assignment of most of
these intermediate cases to discrete diagnostic groups with
predictable clinical behavior and optimized therapy. Until
then, these two new diagnostic categories provide a forum
to study and better understand the biology behind these
complex and aggressive lymphoid neoplasms.
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